Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Principal Investigator
Sharad A. Ghamande
Awardee Organization

Augusta University
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Georgia CaRes

Augusta University has been home to Georgia’s NCI Community Oncology Research Program since 2014. In partnership with University Blood and Cancer Center in Athens, Phoebe Putney Medical Hospital in Albany, Augusta Oncology Associates in Augusta, and Dwight D. Eisenhower Army Medical Center in Augusta, the Georgia CaRes NCORP has over 1550 enrollments in NCI clinical trials (including cancer control, treatment, biospecimens, and special entries). The main goals of this application are to sustain and grow our NCORP Community Site, focusing on improving patient outcomes in cancer care throughout the State of Georgia and beyond. Our original program was aptly named Georgia CaRes (Georgia Cancer Research) and represents our shared commitment to cancer research including studies in cancer control, cancer prevention, and cancer care delivery, as well as clinical trials from NCI’s National Clinical Trials Network (NCTN). The renewal of Georgia CaRes will allow us to continue to serve large portions of the state with high concentrations of rural populations. We will accomplish this through the following Specific Aims: 1) Georgia CaRes will facilitate participation and enrollment of patients and healthcare providers into cancer control, prevention, and cancer cared delivery research (CCDR) studies developed by NCI’s Research Bases and in human research trials of the National Clinical Trials Network (NCTN); 2) Georgia CaRes will support and strengthen NCORP goals by improving the scope of our activities as an NCORP Community Site; 3) Georgia CaRes will increase collaboration across our NCORP Community network and with the Research Bases. Renewal of Georgia CaRes will have a significant and far-reaching impact on the health of cancer patients within the State of Georgia and beyond.

Publications

  • Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 May 15;130(10):1747-1757. Epub 2024 Jan 18. PMID: 38236702
  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 10;39(23):2539-2551. Epub 2021 Jun 6. PMID: 34092112